Spotlight session: CDMO partnerships VS in-house manufacturing: Choosing the right path

Deciding whether to rely on CDMO partnerships or develop internal manufacturing capabilities is critical for advanced therapy developers. This session explores the trade-offs in cost, scalability, quality control, and regulatory compliance, helping organizations make informed decisions for their manufacturing strategy.  

Key takeaways: 

• Compare operational and financial implications of CDMO partnerships versus in-house manufacturing 

• Assess scalability, flexibility, and time-to-market considerations for each approach 

• Evaluate quality control and regulatory compliance requirements in different models 

• Discuss risk management strategies and workforce capability implications 

• Identify decision frameworks to select the most appropriate manufacturing path